allogenic stem cell transplantation
Showing 9976 - 10000 of >10,000
Lymphoma, Non-Hodgkin's Trial in Toronto (Obinutuzumab, Gemcitabine, Dexamethasone)
Completed
- Lymphoma, Non-Hodgkin's
- Obinutuzumab
- +3 more
-
Toronto, Ontario, CanadaPrincess Margaret Cancer Centre
Apr 11, 2021
Bradykinesia Trial in Paducah, Chesterfield, Brentwood (MSCTC-0010)
Recruiting
- Bradykinesia
- MSCTC-0010
-
Paducah, Kentucky
- +2 more
Jan 5, 2021
Serum NGAL asPredictor of Clinical and Endoscopic Activity of
Not yet recruiting
- Inflammatory Bowel Diseases
- (no location specified)
Dec 12, 2021
Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8 Trial
Not yet recruiting
- Anatomic Stage IB Breast Cancer AJCC v8
- +16 more
- CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine
- Sargramostim
-
Seattle, Washington
- +1 more
Jul 27, 2022
Castration-Resistant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen
Recruiting
- Castration-Resistant Prostate Carcinoma
- +7 more
- Biopsy
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Oct 12, 2022
Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative Trial in United States (Anastrozole,
Active, not recruiting
- Anatomic Stage IV Breast Cancer AJCC v8
- +6 more
- Anastrozole
- +6 more
-
Atlanta, Georgia
- +9 more
Oct 12, 2022
The First Affiliated Hospital of Nanchang University Trial in Nanchang, Jinan (Orelabrutinib+R-CHOP)
Recruiting
- The First Affiliated Hospital of Nanchang University
-
Nanchang, Jiangxi, China
- +1 more
Jul 3, 2023
Limbal Stem Cell Deficiency Trial in Guanzhou (Corneal epithelial autograft, Limbal conjunctival autograft, Femtosecond laser)
Unknown status
- Limbal Stem Cell Deficiency
- Corneal epithelial autograft
- +3 more
-
Guanzhou, Guangdong, ChinaZhongshan Ophthalmic Center, Sun Yat-sen Univerisity
Aug 7, 2019
Platelet Aggregation, Spontaneous, Coronary Artery Disease Trial in São Paulo (Colchicine 0.5 MG, Placebo)
Recruiting
- Platelet Aggregation, Spontaneous
- Coronary Artery Disease
- Colchicine 0.5 MG
- Placebo
-
São Paulo, Sao Paulo, BrazilHeart Institute (InCor) / University of São Paulo
Jul 18, 2023
Regional Nodal Basins and Gene Expression Profiling in Primary
Not yet recruiting
- Cutaneous Squamous Cell Carcinoma of the Head and Neck
- Ultrasound
- 40-GEP
- (no location specified)
Jul 12, 2023
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Trial in Nanjing (6-month course of antiandrogen drugs, Long-term course of
Recruiting
- Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
- 6-month course of antiandrogen drugs
- Long-term course of antiandrogen drugs
-
Nanjing, Jiangsu, ChinaUrology dpt, First Affiliated Hospital of Nanjing Medical Univer
Jul 13, 2023
Squamous Cell Carcinoma of Head and Neck, Chemo Induced Nausea and Vomiting Trial (nurse-led standardized intervention)
Not yet recruiting
- Squamous Cell Carcinoma of Head and Neck
- Chemotherapy Induced Nausea and Vomiting
- nurse-led standardized intervention
- (no location specified)
Mar 29, 2023
Squamous Cell Carcinoma of the Oropharynx, HPV Positive Oropharyngeal Squamous Cell Carcinoma Trial in Carmel, Indianapolis (44
Recruiting
- Squamous Cell Carcinoma of the Oropharynx
- HPV Positive Oropharyngeal Squamous Cell Carcinoma
- 44 doses of radiation
- 54 doses of radiation
-
Carmel, Indiana
- +1 more
Oct 5, 2022
Lung Cancer, NSCLC Trial in Tampa (Vorinostat, Pembrolizumab)
Active, not recruiting
- Lung Cancer
- Non-small Cell Lung Cancer
-
Tampa, FloridaH. Lee Moffitt Cancer Center and Research Institute
Nov 10, 2022
Lymphoma, Relapsed/Refractory T-cell Lymphomas Trial in United States (Romidepsin, Bortezomib, duvelisib)
Active, not recruiting
- Lymphoma
- Relapsed/Refractory T-cell Lymphomas
- Romidepsin
- +2 more
-
Stanford, California
- +10 more
Feb 2, 2023
Advanced NSCLC Trial (fianlimab, cemiplimab, Placebo)
Not yet recruiting
- Advanced Non-Small Cell Lung Cancer
- fianlimab
- +2 more
- (no location specified)
Mar 27, 2023
B-Cell Acute Lymphoblastic Leukemia, Adult Trial in La Jolla, Orange, San Francisco (blinatumomab, pembrolizumab)
Terminated
- B-Cell Acute Lymphoblastic Leukemia, Adult
-
La Jolla, California
- +2 more
Apr 26, 2022
Acute Lymphoblastic Leukemia Trial in Shanghai (Human CD19-CD22 Targeted T Cells Injection)
Not yet recruiting
- Acute Lymphoblastic Leukemia
- Human CD19-CD22 Targeted T Cells Injection
-
Shanghai, Shanghai, ChinaRuijin Hospital, Shanghai Jiao Tong University School of Medicin
Jan 24, 2022
COVID-19 Trial in Shang Qiu (low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell), high-dose Recombinant SARS-CoV-2 Vaccine (CHO
Active, not recruiting
- COVID-19
- low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)
- +2 more
-
Shang Qiu, He Nan, ChinaNing ling Center for Disease Control and Prevention
Jan 31, 2023
Amyloidosis, Light Chain (AL) Amyloidosis Trial (Bendamustine Hydrochloride, Isatuximab)
Withdrawn
- Amyloidosis
- Light Chain (AL) Amyloidosis
- Bendamustine Hydrochloride
- Isatuximab
- (no location specified)
Dec 29, 2022
Small-cell Lung Cancer, Brain Metastases Trial in United States (Carboplatin, Etoposide, Atezolizumab)
Active, not recruiting
- Small-cell Lung Cancer
- Brain Metastases
- Carboplatin
- +2 more
-
Duarte, California
- +5 more
Oct 10, 2022
COVID-19 Trial in Changsha (Recombinant new coronavirus vaccine (CHO cell))
Recruiting
- COVID-19
- Recombinant new coronavirus vaccine (CHO cell)
-
Changsha, Hunan, ChinaHunan Provincial Center for Disease Control and Prevention
Oct 10, 2022
Sickle Cell Disease Trial (Shared Decision Making Intervention)
Not yet recruiting
- Sickle Cell Disease
- Shared Decision Making Intervention
- (no location specified)
May 17, 2022